Clinical Trial Update: Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on Abciximab in patients undergoing percutaneous coronary intervention for cardiogenic shock. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiogenic Shock

Drugs mentioned

• Abciximab (abciximab)

Snippet

Sponsor: Charles University, Czech Republic | Conditions: Shock, Cardiogenic | Phase 4 | Status: COMPLETED